# B Group, Inc.

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2043476. Source: https://holderbook.com/funds/2043476-b-group-inc/

- Reported value: $213.0M
- Positions: 19
- Weight of the ten largest: 79.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| INVESCO QQQ TR | [QQQ](https://holderbook.com/stocks/QQQ/) | $36.8M | 0 | 17.3% | 1 |
| ADMA BIOLOGICS INC | [ADMA](https://holderbook.com/stocks/ADMA/) | $27.3M | 3,262,542 | 12.8% | 7 |
| PALISADE BIO INC | [PALI](https://holderbook.com/stocks/PALI/) | $23.9M | 11,414,285 | 11.2% | 3 |
| NRX PHARMACEUTICALS INC | [NRXP](https://holderbook.com/stocks/NRXP/) | $16.7M | 4,091,767 | 7.9% | 2 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $15.3M | 610,169 | 7.2% | 1 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $12.3M | 1,800,556 | 5.8% | 7 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $11.1M | 33,237 | 5.2% | 6 |
| CELLECTIS S A | [CLLS](https://holderbook.com/stocks/CLLS/) | $9.8M | 3,281,501 | 4.6% | 7 |
| ZAI LAB LTD | [ZLAB](https://holderbook.com/stocks/ZLAB/) | $8.6M | 450,646 | 4.0% | 7 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $7.5M | 140,000 | 3.5% | 3 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $7.1M | 75,000 | 3.4% | 7 |
| IOVANCE BIOTHERAPEUTICS INC | [IOVA](https://holderbook.com/stocks/IOVA/) | $6.2M | 1,500,000 | 2.9% | 7 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $6.2M | 70,000 | 2.9% | 7 |
| AURA BIOSCIENCES INC | [AURA](https://holderbook.com/stocks/AURA/) | $5.4M | 764,243 | 2.5% | 7 |
| ASSEMBLY BIOSCIENCES INC | [ASMB](https://holderbook.com/stocks/ASMB/) | $4.8M | 175,706 | 2.3% | 7 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $4.7M | 67,500 | 2.2% | 2 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $4.5M | 135,000 | 2.1% | 7 |
| SIGHT SCIENCES INC | [SGHT](https://holderbook.com/stocks/SGHT/) | $3.7M | 970,000 | 1.7% | 7 |
| FOGHORN THERAPEUTICS INC | [FHTX](https://holderbook.com/stocks/FHTX/) | $976.0K | 200,000 | 0.5% | 2 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +18.3% | +14.8% | +3.4% | 100% |
| Q1 2026 | -24.6% | -4.6% | -20.0% | 100% |
| Q4 2025 | +32.6% | +2.4% | +30.2% | 85% |
| Q3 2025 | +3.8% | +7.8% | -4.0% | 100% |
| Q2 2025 | +7.8% | +10.5% | -2.6% | 100% |
| Q1 2025 | +6.5% | -4.6% | +11.1% | 65% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $213.0M | 19 |
| Q1 2026 | $134.9M | 20 |
| Q4 2025 | $135.4M | 16 |
| Q3 2025 | $135.9M | 20 |
| Q2 2025 | $129.9M | 17 |
| Q1 2025 | $116.7M | 19 |
| Q4 2024 | $163.6M | 18 |